Hospitalization events (95% CI) per 100 patient-years (Group A, before anti-TNF-α treatment, and Group B, during anti-TNF-α treatment).
| Group A | Group B | Female | Male | Ankylosing Spondylitis | Psoriatic Arthritis | Rheumatoid Arthritis | |
|---|---|---|---|---|---|---|---|
| Total events | 74.2 (59.7–92.5) | 44.4 (35–56.2) | 43.7 (35–56.2) | 75.3 (58.3–97.3) | 37.9 (24.6–8.4) | 27.2 (17.7–41.7) | 183.5 (156–215.8) |
| Infection | 4.6 (2.8–7.5) | 7.4 (4.8–11.5) | 2.9 (1.7–4.9) | 11.7 (7.8–17.6) | 3.8 (1.6–7.9) | 3.6 (1.7–7.9) | 14.5 (10.7–19.6) |
| Exacerbation of rheumatic disease | 47.5 (37.9–59.6) | 21.9 (16.7–28.7) | 29.8 (22.9–38.6) | 34.9 (26.7–45.7) | 19.5 (12.4–30.7) | 18 (11.8–27.6) | 95.3 (80.1–113.3) |
| Total orthopedic surgery | 1.6 (0.6–4.3) | 1 (0.3–3.1) | 2.1 (0.8–5.3) | 0.8 (0.2–3) | 1.5 (0.3–7) | 0.5 (0.6–4.2) | 2.6 (1.2–5.5) |
| Orthopedic surgery due to rheumatic diseases | 0.6 (0.1–3.2) | 0.4 (0.07–2.4) | 1.3 (0.4–4.2) | 0.2 (0.01–2.9) | 0.8 (0.1–6.3) | 0.3 (0.1–4) | 0.6 (0.1–3) |
| Total other surgery | 3.2 (1.6–6.2) | 2.3 (1.1–4.8) | 1.1 (0.5–2.8) | 6.4 (3.7–11) | 4.6 (2–10.3) | 1.3 (0.4–4.6) | 3.1 (1.7–5.9) |
| IHD | 0.35 (0.07–1.7) | 0.38 (0.08–1.8) | 0.07 (0.01–0.5) | 1.9 (0.5–7.3) | 0.3 (0.05–2.7) | 0.08 (0.002–2.8) | 1.7 (0.7–4.4) |
TNF: tumor necrosis factor; IHD: ischemic heart disease.